Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 18/20 | 0.51 |
| ▸ | CDK12 | Q9NYV4 | 18/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.51 |
| ▸ | CDK2 | P24941 | 14/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 13/20 | 0.51 |
| ▸ | CDK9 | P50750 | 13/20 | 0.51 |
| ▸ | CDK7 | P50613 | 13/20 | 0.51 |
| ▸ | CCNH | P51946 | 13/20 | 0.51 |
| ▸ | MNAT1 | P51948 | 9/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24584388 | 1.00 | CCNK (0.51) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL24588975 | 0.89 | CCNK (0.63) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL24583148 | 0.89 | CCNK (0.63) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL24583133 | 0.89 | CCNK (0.63) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL24588268 | 0.88 | CCNK (0.46) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL24584008 | 0.88 | CCNK (0.59) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL29083578 | 0.88 | CCNK (0.61) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL24583188 | 0.88 | CCNK (0.61) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL24583279 | 0.87 | CCNK (0.49) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL24584175 | 0.87 | CCNK (0.49) | CCNKCDK12CCNE1CDK2CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132489-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | EXSCIENTIA AI LIMITED (GB) | 2024-04-25 | — | — | US | disclosed |
| EP-4269402-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | GT Apeiron Therapeutics Limited (HK) | 2023-11-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132489-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | CDK7, CDK17, CDK8 | CCNK 39/4885CDK12 38/4885CCNE1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.